Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis

Published:2018-11 Issue:5 Volume:44 Page:393-401
ISSN:1262-3636
Container-title:Diabetes & Metabolism
language:en
Short-container-title:Diabetes & Metabolism

Author:

Cho Y.K.,Kang Y.M.,Lee S.E.,Lee J.,Park J.-Y.,Lee W.J.,Kim Y.-J.,Jung C.H.

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference39 articles.

1. Differentiation of diabetes by pathophysiology, natural history, and prognosis;Skyler;Diabetes,2017

2. Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes;Sharma;Diabetes Obes Metab,2015

3. A review of gliptins for 2014;Scheen;Expert Opin Pharmacother,2015

4. SGLT2 inhibitor/DPP-4 inhibitor combination therapy – complementary mechanisms of action for management of type 2 diabetes mellitus;Dey;Postgrad Med,2017

5. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes;Aschner;Diabetes Care,2006

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-Driven Solutions: Integrating Vildagliptin and Dapagliflozin in Diabetes Management;International Journal of Diabetes and Endocrinology;2024-05-10

2. Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes Mellitus;Journal of Diabetology;2024-04

3. The use of sodium-glucose cotransporter 2 inhibitors and the incidence of uveitis in type 2 diabetes: a population-based cohort study;Archives of Medical Science;2024-02-26

4. Prescribing Patterns of SGLT2 inhibitors and GLP-1 receptor agonists in Patients with T2DM and ASCVD in South Korea;2024-01-30

5. Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review;Terapevticheskii arkhiv;2024-01-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3